Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control

Most systemic viral gene therapies have been limited by sequestration and degradation of virions, innate and adaptive immunity, and silencing of therapeutic genes within the target cells. Here we engineer a high-affinity protein coat, shielding the most commonly used vector in clinical gene therapy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Markus, Ernst, Patrick, Honegger, Annemarie, Suomalainen, Maarit, Zimmermann, Martina, Braun, Lukas, Stauffer, Sarah, Thom, Cristian, Dreier, Birgit, Eibauer, Matthias, Kipar, Anja, Vogel, Viola, Greber, Urs F., Medalia, Ohad, Plückthun, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792622/
https://www.ncbi.nlm.nih.gov/pubmed/29386504
http://dx.doi.org/10.1038/s41467-017-02707-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792622/
https://www.ncbi.nlm.nih.gov/pubmed/29386504
http://dx.doi.org/10.1038/s41467-017-02707-6

Ejemplares similares